ADAMTS13 and thrombotic thrombocytopenic purpura: In refractory or relapsing TTP, rituximab has shown efficacy by depleting B-cells, with some authors advocating for its use in the first episode of iTTP when ADAMTS13 inhibitors are detected [10,11].